Vermont Medicaid GLP-1 Coverage 2026: Pattern #41 — Categorical AOM Exclusion (Weight-Loss + Fertility + Cosmetic + Hair Growth Bundle) With Three Operationalized FDA-Label Carve-Outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) Under FFS-Only Optum-Administered Pharmacy Benefit

TL;DR — what Vermont Medicaid covers and does not cover

The categorical exclusion is anchored verbatim on the Vermont PDL effective April 17, 2026 (page 1, Disclaimer block):

“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”

The Semaglutide MACE/MASH PA Form (Last Updated 04/2026) reaffirms the policy via a mandatory provider attestation:

“Is this medication being used for weight loss only? Yes / No (Per policy Vermont Medicaid does not allow coverage for weight loss products).”

What VT Medicaid does NOT cover (excluded under the categorical AOM bundle):

• Wegovy (semaglutide) for obesity
• Zepbound (tirzepatide) for obesity
• Saxenda (liraglutide) for obesity
• Imcivree (setmelanotide)
• Qsymia (phentermine/topiramate)
• Contrave (naltrexone/bupropion)
• Orlistat (over-the-counter and prescription)
• Phentermine (Adipex-P, Lomaira, generic)

What VT Medicaid DOES cover via three FDA-label-restricted carve-outs (PA required):

What VT Medicaid covers for T2D (GLP-1 Receptor Agonists: Single Agent class):

• Preferred: Exenatide (3 pens / 90 days), Mounjaro (tirzepatide, 12 pens / 84 days), Rybelsus (semaglutide tablets, 1 tablet / day), Trulicity (dulaglutide, 12 pens / 84 days), Victoza (liraglutide, 9 pens / 90 days)
• Non-preferred (PA required): Liraglutide generic (9 pens / 90 days), Ozempic (semaglutide, 9 mL / 84 days), Soliqua (insulin glargine/lixisenatide, 3 pens / 25 days), Xultophy (insulin degludec/liraglutide)

Notable T2D formulary choice: Ozempic is non-preferred in Vermont, while Mounjaro is preferred. Most other states in the series keep Ozempic preferred or both preferred — this is a rebate-driven formulary choice distinctive to Vermont among the New England subset.

Architectural distinctive features:

• Bundled AOM-fertility-cosmetic-hair exclusion — stylistically pre-ACA framing; unusually broad relative to peer states which list weight-loss as a standalone class.
• Three FDA-label carve-outs operationalized via dedicated PA forms — Wegovy MACE + Wegovy MASH share the Semaglutide MACE/MASH PA Form (Last Updated 04/2026); Zepbound OSA has its own drug-specific PA form. Among the cleanest CMS December 2024 OSA-coverage implementations nationally.
• Wegovy MACE BMI threshold = 27 (SELECT trial floor) — more permissive than several southern carve-out states that gate at BMI ≥ 30.
• Wegovy MASH dual-modality F2/F3 confirmation — two non-invasive tests (serologic + image-based) OR biopsy (NAFLD ≥ 4). Intermediate restrictiveness between Utah Pattern #37 (dual-modality required) and peers that accept either modality alone.
• Zepbound OSA > 5% weight-loss reauthorization milestone — mirrors the SURMOUNT-OSA trial endpoint; reauthorization requires 5% weight loss or maintained 5% loss.
• FFS-only architecture — no full-risk capitated MCOs. One PDL, one PBA (Optum), one fax line for all 178,842 Medicaid lives. CMS Managed Care state profile lists Vermont under PCCM.
• Mounjaro preferred + Ozempic non-preferred for T2D — rebate-driven formulary choice distinctive in the series.
• $75M annual fiscal estimate per DVHA on H.765 / S.164 (2024) Medicaid AOM mandate — one of the most candid AOM cost projections any state has published.

Pharmacy benefit architecture:

• PBA: Optum (acquired Change Healthcare 2022); contract #34056 started May 1, 2014; CMS-certified March 28, 2018
• Prescriber PA helpdesk: 1-844-679-5363
• Provider PA fax: 1-844-679-5366 (responses within 24 hours)
• Pharmacy Call Center: 1-844-679-5362
• Member helpdesk: 1-855-899-9600
• Single PDL: applies uniformly across FFS (Vermont has no full-risk Medicaid MCOs)
• PA Forms: Semaglutide MACE/MASH Prior Authorization Form (Last Updated 04/2026) for Wegovy CV and Wegovy MASH; Zepbound OSA Prior Authorization Form for Zepbound; General PA Form for T2D-indicated GLP-1s and other non-preferred drugs

1. Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2)(A) grants states an optional authority to exclude “Agents when used for anorexia, weight loss, or weight gain” from coverage. Vermont has exercised this authority — categorically — and has bundled the weight-loss exclusion with fertility, cosmetic, and hair-growth drug exclusions in a single PDL Disclaimer.

Unlike Maine Pattern #39 (which anchors the exclusion in a freestanding state regulation at 10-144 C.M.R. ch. 101, Ch. II, § 80.06(A)), Vermont operates the exclusion at the PDL-policy level only. There is no Vermont counterpart to Maine’s § 80.06(A) regulation specifically naming weight-loss drugs — the PDL Disclaimer block is the primary publicly accessible statement of the policy.

The three FDA-label-restricted carve-outs (Wegovy MACE, Wegovy MASH, Zepbound OSA) operate as exceptions at the PA-form level. Vermont has NOT executed a State Plan Amendment carve-back-in pathway (in contrast to Mississippi Pattern #35’s SPA 23-0013); instead the carve-outs operate via PDL coding (preferred status under Cardiometabolic Health Agents and Obstructive Sleep Apnea classes) plus indication-specific PA forms.

2. PDL anchor: Vermont Preferred Drug List effective April 17, 2026

The Vermont Preferred Drug List effective April 17, 2026 is the binding policy document for Vermont Medicaid pharmacy coverage. The Disclaimer block on page 1 reads verbatim:

“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”

This bundled-exclusion framing is the broadest in the New England subset and one of the broadest in the 41-state series. It captures four distinct categories of drugs that share the common policy framing of “optional” or “non-medically-necessary” use — a framing rooted in the federal Medicaid statute’s § 1396r-8(d)(2) optional-exclusion list, which encompasses weight-loss agents, fertility agents, cosmetic-purpose agents (such as those for hair growth), and several other categories.

The PDL has been revised several times in the past 12 months. The currently effective April 17, 2026 version is preceded by the January 1, 2026 PDL. Both versions contain the same Disclaimer-block exclusion language. The PDL revision cadence is approximately quarterly, driven by the DVHA Drug Utilization Review (DUR) Board recommendations and CMS-required formulary updates.

Within the PDL, the three carve-out drugs (Wegovy injectable, Zepbound) are positioned as follows:

• Wegovy (semaglutide) injectable — Preferred under Cardiometabolic Health Agents therapeutic class with quantity limit 4 pens / 28 days. Wegovy tablets are non-preferred within the same class (requires documented treatment failure with the preferred injectable). Rezdiffra (resmetirom) and Lodoco (colchicine) are also non-preferred within Cardiometabolic Health Agents.
• Zepbound (tirzepatide) — Preferred under a standalone Obstructive Sleep Apnea therapeutic class. This is one of the cleanest CMS December 2024 OSA-coverage implementations in the series — a dedicated PDL class, a drug-specific PA form, and a > 5% weight-loss reauthorization milestone that directly references the SURMOUNT-OSA trial endpoint.

3. Wegovy CV/MACE carve-out (Cardiometabolic Health Agents PDL class)

Per the Semaglutide MACE/MASH Prior Authorization Form (Last Updated 04/2026), the indication-for-use heading reads “Major Adverse Cardiac Event (MACE) Reduction”. Criteria verbatim:

“Medication is not being used for weight loss only

Patient does not have diagnosis of diabetes

Patient has received counseling on chronic weight management (increased physical activity and a reduced calorie diet) and will continue to follow a treatment plan

Patient has BMI > 27 kg/m²

Patient has history of at least one of the following: Stroke; Myocardial Infarction; Symptomatic peripheral arterial disease

For Wegovy tablet: patient must have a documented treatment failure with the preferred injectable semaglutide product

Initial approval will be for 6 months, for reapproval: patient must continue to follow a reduced calorie diet and increased physical activity plan AND provider attests to clinical benefit (reduction in cardiovascular health risks).”

3.1 BMI > 27 threshold at the SELECT trial floor

Vermont’s BMI threshold of strictly greater than 27 kg/m² matches the SELECT trial entry criterion and is more permissive than several southern Wegovy MACE carve-out states that gate at BMI ≥ 30 or impose additional comorbidity requirements. The threshold mirrors Maine Pattern #39’s BMI > 27 strictly-greater language — both are New England categorical-exclusion states with carve-outs anchored at the SELECT floor.

A Vermont patient with BMI exactly 27.0 kg/m² would fail the Vermont criteria but would pass equivalent criteria in West Virginia Pattern #36 (which accepts ≥ 27 inclusive). In practice, BMI is reported to one decimal place, so the operational impact is small — but appeal documentation should report BMI to the highest available precision (e.g., 27.4 kg/m², not 27 kg/m²).

3.2 The “not for weight loss only” attestation

The first criterion — “Medication is not being used for weight loss only” — is the operative anchor that distinguishes the MACE carve-out from the categorical chronic-weight-management exclusion. The attestation is mandatory and links to the PDL Disclaimer’s exclusion of “drugs used for weight loss.” A clinical note documenting the cardiovascular indication (MI / stroke / symptomatic PAD) is the gating evidence.

3.3 The “symptomatic” PAD requirement

Vermont specifies symptomatic peripheral arterial disease — not just PAD with abnormal ankle-brachial index (ABI). This is more restrictive than several state Wegovy CV carve-outs that accept asymptomatic PAD with documented ABI ≤ 0.9 or equivalent vascular imaging findings. Vermont appeal documentation for PAD-based eligibility should include both objective PAD findings (ABI ≤ 0.9, peripheral revascularization, amputation) AND clinical symptom documentation (claudication symptoms, rest pain, non-healing wounds).

3.4 Wegovy tablet step-therapy from preferred injectable

For Wegovy tablet (oral semaglutide for cardiovascular risk reduction), Vermont requires “documented treatment failure with the preferred injectable semaglutide product”. This is a within-class step-therapy that routes patients first to the preferred injectable formulation and only to the oral tablet after documented failure. The treatment-failure definition is not explicitly spelled out on the PA form for Wegovy tablet (the < 1% HbA1c reduction at 12 weeks definition appears for T2D-indicated GLP-1s but not the CV carve-out) — appeal documentation should document objective intolerance (injection-site reactions, needle phobia with documented psychiatric or behavioral health diagnosis) or clinical-judgment-based failure.

3.5 6-month initial / reauthorization with cardiovascular benefit attestation

Initial approval is for 6 months; reauthorization requires the patient to “continue to follow a reduced calorie diet and increased physical activity plan AND provider attests to clinical benefit (reduction in cardiovascular health risks).” The cardiovascular-benefit attestation is structurally different from the weight-loss-milestone attestation used in the Zepbound OSA carve-out — for MACE, the reauthorization gates on the prescriber’s clinical judgment about CV risk reduction, not on a specific weight-loss percentage.

4. Wegovy MASH carve-out (Cardiometabolic Health Agents PDL class)

Vermont is one of a small minority of states in the 41-state series with a fully operationalized Wegovy MASH (metabolic dysfunction-associated steatohepatitis) carve-out following the August 2025 FDA-label expansion. The indication is for the injectable formulation only (not tablets). Per the Semaglutide MACE/MASH PA Form (Last Updated 04/2026), criteria verbatim:

“Patient has metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (consistent with stages F2 or F3 fibrosis) documented by either a combination of two non-invasive tests (serologic and image-based) or biopsy (NAFLD ≥ 4)

Patient does not have evidence of decompensated cirrhosis

Medication is being prescribed or in consultation with gastroenterologist, hepatologist, or endocrinologist

Initial approval will be for 6 months, for reapproval: Patient must continue to follow a reduced calorie diet and increased physical activity plan AND provider attests to clinical benefit with documentation of positive clinical response (no progression to stage F4 fibrosis).”

4.1 Dual-modality F2/F3 fibrosis confirmation

Vermont accepts F2/F3 fibrosis confirmation by either (a) a combination of two non-invasive tests (one serologic + one image-based) OR (b) biopsy with NAFLD activity score ≥ 4. This dual-modality pathway is intermediate in restrictiveness between Utah Pattern #37 (which requires both modalities) and several peer states that accept either modality alone. The two-non-invasive-tests pathway is the operational default for most patients because liver biopsy is invasive and reserved for diagnostically uncertain cases.

Serologic non-invasive tests commonly used: FIB-4 index (calculated from age, AST, ALT, platelet count), ELF (Enhanced Liver Fibrosis) score, NAFLD Fibrosis Score (NFS).

Image-based non-invasive tests commonly used: Vibration-controlled transient elastography (VCTE / FibroScan), MR elastography (MRE), shear-wave elastography (SWE).

For F2/F3 documentation, a typical combination pathway is FIB-4 > 2.67 (suggestive of advanced fibrosis) + VCTE liver stiffness measurement 8–14 kPa (F2–F3 range), or ELF score > 9.8 + MRE 2.99–4.7 kPa.

4.2 Decompensated cirrhosis exclusion

The PA form excludes patients with “evidence of decompensated cirrhosis”. Decompensated cirrhosis presents with one or more of: hepatic encephalopathy, ascites, variceal hemorrhage, jaundice. The exclusion mirrors the ESSENCE trial population (compensated noncirrhotic MASH F2-F3 fibrosis) and parallels the FDA label expansion.

4.3 GI / hepatology / endocrinology consult requirement

The prescription must be from “gastroenterologist, hepatologist, or endocrinologist”, or be prescribed in consultation with one. Primary care physicians cannot directly prescribe under this carve-out without subspecialty input. The endocrinology pathway is unusual in MASH PA criteria — most states limit prescribing to GI/hepatology — and reflects the metabolic-syndrome framing of MASH that places endocrinologists alongside GI in the prescribing pool.

4.4 6-month reauthorization with no-F4-progression attestation

Initial approval is for 6 months; reauthorization requires the prescriber to attest to “clinical benefit with documentation of positive clinical response (no progression to stage F4 fibrosis)”. The structural anchor for reauthorization is fibrosis-stage stability rather than weight loss — reflecting the MASH-specific clinical endpoint rather than the obesity-treatment endpoint. Practical reauthorization evidence: serial non-invasive testing showing stable or improved fibrosis markers, OR a biopsy showing no progression to F4.

5. Zepbound OSA carve-out (Obstructive Sleep Apnea PDL class)

Per the Zepbound OSA Prior Authorization Form, Zepbound is preferred under a standalone Obstructive Sleep Apnea therapeutic class. Criteria verbatim:

“Patient has a diagnosis of obstructive sleep apnea (OSA) demonstrated by a sleep study with an AHI (events per hour) > 15 and meets the following criteria:

BMI > 30 kg/m²

Has been prescribed CPAP therapy

Has received counseling on chronic weight management (increased physical activity and a reduced calorie diet) and will continue to follow a treatment plan

Does not have T2DM

Does not have NYHA Class IV Heart Failure

Has not had a serious cardiac event in the previous 3 months (acute MI, stroke, unstable angina, or hospitalization due to heart failure)

Initial approval will be for 6 months, for reapproval: Patient must continue to follow a reduced calorie diet and increased physical activity plan AND patient has shown a documented weight loss of > 5% of baseline body weight OR continued to maintain initial 5% weight loss.”

5.1 AHI > 15 threshold (moderate-to-severe OSA)

Vermont’s AHI threshold of strictly greater than 15 events per hour corresponds to the moderate-to-severe OSA cutoff and directly references the SURMOUNT-OSA trial entry criterion. Sleep study report must document AHI value. The PA form does not specify a sleep-study look-back window — most state OSA carve-outs require the study to be within 12–36 months. Vermont’s lack of an explicit look-back window is more permissive than Maine Pattern #39 (3-year window), Nebraska Pattern #38 (24-month window), or Oklahoma Pattern #24 (12-month window) — but a recent study is preferred to demonstrate current OSA severity.

5.2 BMI > 30 threshold for OSA

Vermont’s BMI threshold for OSA is strictly greater than 30 kg/m² — matching the SURMOUNT-OSA trial entry criterion. The higher OSA BMI (compared to the MACE BMI > 27 threshold) reflects the OSA-specific evidence base and the FDA label.

5.3 “Has been prescribed CPAP therapy” — not CPAP failure

Vermont’s OSA carve-out language requires the patient to have been prescribed CPAP therapy — not necessarily to have failed CPAP. This is more permissive than several state OSA carve-outs (e.g., West Virginia Pattern #36 requires CPAP counseling; Maine Pattern #39 requires CPAP “ineffective or intolerant for 90 days”; Utah Pattern #37 requires 70% PAP adherence then failure). Vermont’s prescription-alone standard is the lowest documented CPAP-prerequisite bar in the New England subset of the series.

5.4 T2DM exclusion routes T2D-with-OSA patients elsewhere

The Zepbound OSA carve-out excludes patients with T2DM. T2D patients with OSA are routed instead through the T2D pharmacy pathway — Mounjaro (tirzepatide) is preferred for T2D under the Peptide Hormones – GLP-1 Receptor Agonists: Single Agent class, with PA criteria gated on the diagnosis of T2D and the < 1% HbA1c reduction at 12 weeks treatment-failure definition. A T2D patient with OSA cannot stack the OSA carve-out with the T2D pathway; the T2D indication takes precedence.

5.5 NYHA Class IV HF + 3-month serious-cardiac-event exclusions

The OSA carve-out excludes patients with NYHA Class IV heart failure (advanced/end-stage HF with severe limitation of activity) and patients with a serious cardiac event in the preceding 3 months (acute MI, stroke, unstable angina, or hospitalization due to heart failure). The 3-month look-back operationalizes the SURMOUNT-OSA trial exclusion criteria and reflects the safety framing of starting tirzepatide in the post-event window.

5.6 > 5% weight-loss reauthorization milestone (or maintained 5% loss)

Reauthorization at 6 months requires “documented weight loss of > 5% of baseline body weight OR continued to maintain initial 5% weight loss”. The 5% threshold mirrors the SURMOUNT-OSA trial endpoint and the FDA-approved labeling expectation. The “or maintained 5% loss” option allows patients past the initial 6 months to continue therapy as long as they hold the loss — rather than requiring continued progressive loss indefinitely. This is operationally important for adolescents and adults near weight-loss plateaus.

6. T2D-indicated GLP-1 PDL coverage

Type 2 diabetes-indicated GLP-1 receptor agonists are covered under the Vermont PDL Peptide Hormones – GLP-1 Receptor Agonists: Single Agent therapeutic class. Coverage is universal for T2D when PA criteria are met (Vermont is not a categorical-exclusion state for T2D-indicated GLP-1 use).

PA criteria verbatim:

“Clinical criteria for all drugs: patient has a diagnosis of Type 2 Diabetes Mellitus. Treatment failure for GLP-1 products is defined as <1% reduction in HbA1c after 12 weeks at the maximally tolerated dose.

Liraglutide, Ozempic: Patient has a documented side effect, allergy, contraindication, or treatment failure with a preferred product. For liraglutide, the patient must be unable to use brand equivalent.

Soliqua/Xultophy: patient has a documented side effect, allergy, contraindication, or treatment failure with at least one preferred GLP-1 Receptor Agonist used in combination with Lantus. Treatment failure is defined as < 1% reduction in HbA1c after 12 weeks at the maximally tolerated dose.”

6.1 Ozempic non-preferred — rebate-driven formulary choice

Vermont’s decision to place Ozempic on the non-preferred tier and Mounjaro on the preferred tier for T2D is rebate-driven and distinctive in the New England subset. Most peer state Medicaid programs (including Massachusetts) keep Ozempic preferred for T2D given prescriber familiarity and patient continuity. A Vermont prescriber writing a fresh T2D semaglutide prescription will face a step-therapy or therapeutic-substitution hurdle that routes the patient first to a preferred drug (Mounjaro, Trulicity, Victoza, Rybelsus, Exenatide). For an established Ozempic patient transitioning into Vermont Medicaid from commercial insurance, the prescriber should document the prior side-effect / allergy / contraindication / treatment-failure history with the preferred alternatives to support the non-preferred Ozempic PA.

6.2 < 1% HbA1c reduction at 12 weeks — treatment-failure definition

Vermont’s treatment-failure definition is “<1% reduction in HbA1c after 12 weeks at the maximally tolerated dose”. This is a clinically reasonable definition that requires HbA1c monitoring on a 12-week cadence during titration. Practical implication: prescribers should document baseline HbA1c, dose escalation, and follow-up HbA1c at 12 weeks of maximum tolerated dose to support a step-therapy override or non-preferred PA submission.

7. PA submission process end-to-end

Three PA forms govern the Vermont Medicaid GLP-1 carve-out and T2D pathways:

• Semaglutide MACE/MASH Prior Authorization Form (Last Updated 04/2026) — covers Wegovy CV and Wegovy MASH. URL: dvha.vermont.gov — Semaglutide MACE/MASH PA Form
• Zepbound OSA Prior Authorization Form — covers Zepbound for OSA. URL: dvha.vermont.gov — Zepbound OSA PA Form
• General Prior Authorization Form — covers T2D-indicated GLP-1s (Mounjaro, Trulicity, Victoza, Rybelsus, Exenatide preferred; liraglutide generic, Ozempic, Soliqua, Xultophy non-preferred) and other non-preferred drugs. URL: dvha.vermont.gov — General PA Form

Form direction verbatim:

“For members to receive Medicaid coverage for medications that require prior authorization, the prescriber must complete and fax this form to Optum. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information. For questions, please contact the Optum helpdesk at 1-844-679-5363. Submit request via Fax: 1-844-679-5366.”

7.1 Step-by-step submission

1. Confirm indication and select the correct form. Wegovy CV or Wegovy MASH = Semaglutide MACE/MASH PA Form. Zepbound OSA = Zepbound OSA PA Form. T2D-indicated GLP-1 = General PA Form.
2. Document the patient's diagnosis with ICD-10 code. For Wegovy MACE: I63.x (cerebral infarction), I21.x (acute MI history), I70.21x (atherosclerosis of native arteries of extremities with intermittent claudication, symptomatic PAD). For Wegovy MASH: K76.81 (NASH / MASH). For Zepbound OSA: G47.33 (OSA).
3. Document BMI to one decimal place. Wegovy MACE: BMI > 27. Zepbound OSA: BMI > 30. Always report to highest available precision.
4. Attach indication-specific clinical evidence. Wegovy MACE: cardiology consult note, ECG / cath / imaging showing prior MI / stroke / symptomatic PAD. Wegovy MASH: F2/F3 fibrosis documentation (FIB-4 + VCTE for two-non-invasive-tests pathway, or biopsy NAFLD ≥ 4) + GI / hepatology / endocrinology consult note. Zepbound OSA: sleep study report with AHI value, CPAP prescription, exclusion documentation for T2DM / NYHA IV HF / 3-month serious cardiac event.
5. Complete “weight-loss only” attestation. The mandatory PA form attestation asks: “Is this medication being used for weight loss only? Yes / No.” Indicate NO and reference the FDA-label indication being claimed.
6. Fax to Optum at 1-844-679-5366. The fax line responds within 24 hours.
7. For questions, call 1-844-679-5363. The Optum helpdesk is the operative point of contact during PA review.
8. Receive approval / denial decision. Initial approval is for 6 months for all three carve-outs (MACE, MASH, OSA).
9. At 6 months, submit reauthorization request. Wegovy MACE: prescriber attests to clinical benefit (reduction in cardiovascular health risks) + continued lifestyle intervention. Wegovy MASH: documentation of no progression to stage F4 fibrosis + continued lifestyle. Zepbound OSA: documented > 5% weight loss from baseline OR maintained 5% loss + continued lifestyle.

8. Appeals pathway: two-step (DVHA internal → Human Services Board fair hearing)

Vermont Medicaid uses a two-step appeals pathway anchored in Code Vt. R. 13-001-008-X PART EIGHT (Rules Governing Appeals to the Human Services Board). The regulatory citation is the binding anchor.

8.1 Step 1 — Internal Appeal to DVHA

• Filing deadline: within 60 calendar days of the adverse decision
• Decision timeline: within 30 days of receipt; may be extended 14 additional days
• Aid-paid-pending: must be requested at the time of appeal filing (coverage continues during the internal appeal if requested)
• Expedited internal appeal verbatim: “Emergency expedited appeals may be requested in situations when you believe that the time for a regular appeal could risk your life or health.”
• File by mail: Health Care Appeals Team, DVHA, 150 Pilgrim Park, Waterbury, VT 05676
• File by phone: Customer Support 1-800-250-8427 / TDD-TTY 1-888-834-7898
• Internal Appeals guide PDF: dvha.vermont.gov — State of Vermont DVHA Internal Appeals

8.2 Step 2 — Fair Hearing before the Human Services Board

The Human Services Board is verbatim “a citizen’s panel consisting of seven members created by the legislature to act as a fair hearing board for appeals brought by individuals who are aggrieved by decisions or policies of departments and programs within the Agency of Human Services.”

• Filing deadline: within 120 days of the internal-appeal decision letter date
• File methods (verbatim from Internal Appeals PDF):
• (1) Call Customer Support 1-800-250-8427 OR HSB 802-828-2536
• (2) Email AHS.COHSBContact@vermont.gov
• (3) Online: hsb.my.vermont.gov/s/
• (4) Mail to: Human Services Board, 14-16 Baldwin Street, 2nd floor, Montpelier, VT 05633-4301
• (5) In person

8.3 Free legal representation

Vermont Legal Aid Office of Health Care Advocate: 1-800-917-7787 / vtlawhelp.org. Free representation for Medicaid appeals, including representation at Human Services Board fair hearings.

8.4 Practical denial-recovery strategy

1. First, call the Optum helpdesk at 1-844-679-5363. Many denials are documentation deficiencies recoverable via re-submission of the same PA form with additional clinical evidence. Verify the denial rationale before initiating an internal appeal.
2. If the denial is substantive (criteria-based), re-submit the PA form with stronger evidence. For Wegovy MACE denials based on insufficient CVD documentation, add a cardiology consult note + objective imaging. For Wegovy MASH denials based on F2/F3 documentation, add FIB-4 + VCTE or biopsy NAFLD score documentation. For Zepbound OSA denials based on T2DM exclusion or 3-month cardiac event exclusion, document the absence of these conditions explicitly.
3. If re-submission fails, file the internal appeal within 60 days. Request aid-paid-pending at the time of filing. If urgency is medically necessary, request expedited review.
4. If internal appeal denies, file fair hearing within 120 days. The Human Services Board is independent of DVHA and can overturn DVHA decisions.
5. Contact Vermont Legal Aid Office of Health Care Advocate (1-800-917-7787) for free representation. The Health Care Advocate office specifically handles Medicaid appeals.

9. Recent legislative activity: H.765 / S.164 (2024)

9.1 H.765 — House companion

H.765 (“An act relating to health insurance coverage for obesity care”) was introduced in the 2024 session by Representative Mari Cordes (Lincoln) with 14 cosponsors including Anthony, Black, Bos-Lun, Burrows, Cina, Elder, Farlice-Rubio, Headrick, LaBounty, Logan, McCann, McGill, Priestley, and Stebbins.

Statement of purpose verbatim:

“This bill proposes to require health insurance, including Medicaid, to provide comprehensive coverage of treatment for obesity.”

The bill would have added 8 V.S.A. § 4088n requiring covered plans (explicitly including Medicaid) to provide:

“(1) coverage of anti-obesity medications approved by the U.S. Food and Drug Administration at levels that are adequate to meet patient needs, including covering at least one anti-obesity drug from the GLP-1 class for weight loss and at least two additional oral anti-obesity medications; (2) coverage of access to effective lifestyle interventions, including nutrition counseling, nutrient tracking, and exercise planning and tracking with coaching; (3) coverage of surgery for treatment of obesity, including bariatric surgery; and (4) providing access to a range of obesity treatment options and ensuring nondiscriminatory access to safe, clinically appropriate drug therapy for members with chronic conditions, including drug therapies indicated for adolescents 12 years of age and older.”

Effective date in the bill: January 1, 2025. Status: introduced 2024; did not advance.

9.2 S.164 — Senate companion

S.164 (“An act relating to health insurance coverage for obesity care”) was introduced January 3, 2024 by Sen. Ruth Hardy and Sen. Kesha Ram Hinsdale. The bill was referred to the Senate Committee on Finance, which held committee hearings on January 10 and January 24, 2024 with testimony from the American Diabetes Association, Blue Cross Blue Shield of Vermont, and UVM Medical Center physicians. Status: did not pass. No Act assigned.

9.3 The DVHA $75M fiscal estimate

Per VtDigger (February 18, 2024), DVHA spokesperson Alex McCracken told lawmakers:

“These are very popular medications, and they do carry significant costs.”

DVHA’s preliminary estimate was that requiring Medicaid AOM coverage “could cost the state approximately $75 million annually in drug costs within a few years.” This is one of the most candid AOM cost projections any state Medicaid agency has published. The estimate functions as a benchmark for the fiscal pressure that has stalled comparable legislation in other categorical-exclusion states (e.g., Maine LD 480’s $42M-$53M fiscal note, Nebraska LB907’s $42.4M fiscal note).

9.4 H.815 (2026) and successor legislation — UNVERIFIED

As of May 15, 2026, we have not located a confirmed reintroduction of the H.765 / S.164 AOM-mandate framework in the 2025-26 biennium. H.815 (2026) has been referenced in legislative tracking but the full text is not yet posted; the title is generic (“reimbursement for certain health care services”) and does not specifically commit to AOM coverage in the readable summary. Readers should track legislature.vermont.gov for successor legislation as the 2026 session progresses.

10. UNVERIFIED items — flagged honestly

Per Weight Loss Rankings’ YMYL 125% accuracy standard, the following items are flagged as UNVERIFIED rather than fabricated. These are gaps in the publicly available Vermont Medicaid primary sources that readers should verify independently:

1. Wegovy pediatric (ages 12+) for obesity coverage status. The April 17, 2026 PDL does not address pediatric obesity-indicated Wegovy. Default position is excluded under the categorical “drugs used for weight loss” exclusion. The 2024 H.765 bill text explicitly named “drug therapies indicated for adolescents 12 years of age and older” as part of the proposed mandate, which implies current policy does not cover pediatric Wegovy for obesity. A definitive answer requires direct query to the Optum prescriber helpdesk (1-844-679-5363) or a fair-hearing precedent.
2. H.765 / S.164 (2024) successor bill in the 2025-2026 biennium. No confirmed reintroduction located. H.815 (2026) is referenced in legislative tracking with a generic title but the full bill text is not yet posted.
3. Sleep-study look-back window for Zepbound OSA. The Zepbound OSA PA Form does not specify a maximum age for the AHI-documenting sleep study. Most state OSA carve-outs gate at 12-36 months. Vermont’s lack of an explicit window is operationally permissive but may be subject to clinical-judgment review during PA adjudication.
4. Imcivree (setmelanotide) coverage for genetic obesity disorders. Imcivree is FDA-approved for chronic weight management in patients with POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome. The PDL April 17, 2026 categorical AOM exclusion would presumptively exclude Imcivree, but Imcivree has historically been routed via a Genetic Obesity Disorders carve-back-in pathway in several states (e.g., MS Pattern #35). Vermont’s position is not explicitly addressed in the readable PDL.

If you encounter any of these gaps in practice, please contact us with the documentation and we will update this article with verified primary-source language.

11. How Vermont Pattern #41 fits the 50-state series

Vermont (Pattern #41) is the architecturally cleanest categorical-exclusion-plus-carve-outs state in the New England subset and one of the cleanest in the 41-state series overall. The 41-state series to date documents four coverage-architecture types:

11.1 Vermont vs. Maine (Pattern #39) — closest peer

Vermont and Maine are the two New England categorical-exclusion states with the most architecturally similar postures. Both anchor a categorical chronic-weight-management exclusion with narrow FDA-label-restricted carve-outs. Both use Optum as the PBM. Both are FFS-dominant.

Key differences:

• MASH coverage: Vermont covers Wegovy MASH (F2/F3 fibrosis via dual-modality non-invasive tests or biopsy NAFLD ≥ 4). Maine does NOT cover Wegovy MASH (the GI/NASH PDL category covers only Rezdiffra). Vermont is the more permissive carve-out posture despite the same categorical baseline.
• OSA CPAP prerequisite: Vermont requires the patient to have been prescribed CPAP therapy (the lowest documented CPAP-prerequisite bar in the New England subset). Maine requires CPAP “ineffective or intolerant for 90 days”. Vermont’s lower bar means a patient newly diagnosed with OSA can theoretically access Zepbound without first failing CPAP.
• Exclusion bundle: Vermont bundles weight-loss with fertility, cosmetic, and hair-growth drugs in a single PDL Disclaimer block. Maine separates weight-loss as a standalone Section 80.06(A) state regulation. The Vermont framing is unusually broad; the Maine framing is unusually specific.
• Architecture: Vermont is purely FFS-only (PCCM, no MCOs, no full-risk capitated care). Maine is FFS-dominant with PCMH and health-home programs supplementing FFS.
• Successor legislation status: Maine’s LD 480 was reported Ought-Not-To-Pass on March 20, 2025 (a definitive disposition). Vermont’s H.765 / S.164 stalled in committee without a definitive Ought-Not-To-Pass disposition, leaving the proposals in a softer fail state.

11.2 Vermont vs. Rhode Island (Pattern #40) — inverse comparison

Vermont and Rhode Island represent inverse postures in the New England subset. RI currently covers baseline AOM (Wegovy, Zepbound, Saxenda, Contrave for obesity) but faces a governor-proposed October 1, 2026 sunset; VT excludes baseline AOM but operationalizes three carve-outs (CV + MASH + OSA).

• Reader question framing: RI patients ask “will my existing coverage survive the legislature?” VT patients ask “do I qualify for any of the three carve-outs?”
• Coverage breadth: RI’s current coverage is broader (covers obesity baseline). VT’s coverage is narrower in scope (only three indication-specific carve-outs) but unified statewide because of FFS-only architecture.
• Architecture: VT is FFS-only (no MCOs); RI consolidated to two MCOs (NHPRI + UHC) effective July 1, 2025 plus EOHHS FFS PDL as floor.
• Fiscal pressure: RI’s sunset proposal is driven by “PMPM roughly quadrupled” cost growth ($20.3M all-funds savings). VT’s H.765 / S.164 stalled under DVHA’s $75M annual fiscal estimate — the same magnitude of cost concern that drove RI’s sunset proposal but applied at the front end of the policy question (don’t add the coverage) rather than the back end (remove existing coverage).

11.3 New England subset summary

With Vermont Pattern #41 shipped, the New England subset of the 50-state series is now substantially covered. The remaining states (Massachusetts, Connecticut, New Hampshire) follow distinct architectures:

• Massachusetts — active-coverage state with parallel sunset proposal under MassHealth (pending publication in series)
• Connecticut — PCCM-dominant architecture with separately administered RX (pending publication in series)
• New Hampshire — coverage previously dropped (cash-pay or compounded telehealth path)
• Maine Pattern #39 — categorical exclusion + 2 carve-outs (no Wegovy MASH)
• Rhode Island Pattern #40 — active coverage with October 1, 2026 sunset proposal
• Vermont Pattern #41 — categorical exclusion + 3 carve-outs (CV + MASH + OSA) under FFS-only architecture

12. What Vermont Medicaid beneficiaries should do right now

If you have established cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) AND BMI > 27 AND no diabetes diagnosis: you may qualify for the Wegovy MACE carve-out. Ask your prescriber to file the Semaglutide MACE/MASH PA Form (Last Updated 04/2026) with the indication of “Major Adverse Cardiac Event (MACE) Reduction.” Document the qualifying CVD event with cardiology consult notes and objective imaging (ECG, cath, MRI). For symptomatic PAD specifically, document both the objective findings (ABI ≤ 0.9, peripheral revascularization, amputation) AND clinical symptoms (claudication, rest pain, non-healing wounds). Initial approval is for 6 months; reauthorization requires the prescriber to attest to clinical benefit (CV risk reduction).

If you have biopsy-proven or non-invasive-test-confirmed F2/F3 MASH with no decompensated cirrhosis: you may qualify for the Wegovy MASH carve-out. Engage a gastroenterologist, hepatologist, or endocrinologist to prescribe or co-sign the PA. Document F2/F3 fibrosis either by biopsy (NAFLD activity score ≥ 4) or by combination of two non-invasive tests (one serologic such as FIB-4 + one image-based such as VCTE / FibroScan / MRE). Initial approval is for 6 months; reauthorization requires documented no progression to F4 fibrosis on follow-up testing.

If you have moderate-to-severe OSA (AHI > 15 from a sleep study) AND BMI > 30 AND a CPAP prescription AND no T2D AND no NYHA Class IV HF AND no serious cardiac event in the past 3 months: you may qualify for the Zepbound OSA carve-out. The Zepbound OSA PA Form is the operative form. Initial approval is for 6 months; reauthorization requires documented > 5% weight loss from baseline OR maintained 5% loss. Begin tracking weight at the start of therapy to support reauthorization.

If you have T2D: the standard T2D pharmacy pathway applies via the General PA Form. Mounjaro (tirzepatide) is preferred and is the first-line GLP-1 option. If you are an established Ozempic patient transitioning to Vermont Medicaid, document the prior side-effect / allergy / contraindication / treatment-failure history with preferred alternatives to support the non-preferred Ozempic PA. Treatment failure is defined as < 1% HbA1c reduction at 12 weeks at the maximally tolerated dose.

If you have none of these qualifying indications: Vermont Medicaid will not cover GLP-1 receptor agonists for obesity. Practical paths: (1) NovoCare Wegovy cash-pay ($199-$349/month depending on dose; HD pen at $399/month; oral semaglutide tablets at $149/month); (2) LillyDirect Zepbound vials at $299-$699/month; (3) LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month; (4) patient assistance programs (Novo Nordisk PAP, Lilly Cares) for income-tested support; (5) LegitScript-approved compounded telehealth at $99-$199/month for semaglutide and $149-$249/month for tirzepatide (with the FDA compounding-resolved caveat for both molecules).

If your PA is denied: do not give up after the first denial. Call the Optum helpdesk at 1-844-679-5363 to verify denial rationale — many denials are documentation deficiencies recoverable via re-submission. If the denial is criteria-based, re-submit with stronger clinical evidence. If re-submission fails, file an internal appeal with DVHA within 60 calendar days; request aid-paid-pending at the time of filing. If the internal appeal fails, file a fair-hearing request with the Human Services Board within 120 days. Contact Vermont Legal Aid Office of Health Care Advocate (1-800-917-7787) for free representation.

Related coverage

• Hawaii Med-QUEST GLP-1 Coverage (Pattern #50 CAPSTONE / SERIES COMPLETE) — closest formulary-language peer to VT in the entire 50-state series: HI AlohaCare verbatim “Drugs for weight loss, erectile dysfunction, infertility, and cosmetic purposes are not covered” vs. VT PDL verbatim “Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage” — both bundle three of the six federal SSA 1927(d)(2)(A) optional-exclusion categories (weight loss + fertility + cosmetic). VT FFS-only vs. HI 5-MCO mandatory managed care under 32-year continuous 1115 demonstration (CMS 11-W-00001/9 since August 1, 1994, longest in series). VT operationalizes three FDA-label carve-outs via drug-specific PA forms (Wegovy MACE + Wegovy MASH + Zepbound OSA); HI carve-outs UNVERIFIED (binary-PDF MCO PDLs). VT H.765 / S.164 (2024) stalled in committee; HI SB 3195 (Sen. Kurt Fevella R-Ewa Beach, bipartisan, 2026 Regular Session) live in 2-year biennial legislature. Pattern #50 closes the 50-state series
• Alaska Medicaid GLP-1 Coverage (Pattern #49) — closest peer architecturally for FFS-only no-MCO categorical-exclusion state: both VT and AK operate single statewide PDLs with no plan-by-plan formulary fragmentation, but VT operationalizes three FDA-label carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) via drug-specific PA forms while AK has neither the carve-out forms nor the published carve-out criteria (Wegovy / Zepbound / Saxenda absent from any class of the March 1, 2026 PDL); AK uses a single General PA Form for ALL non-preferred drugs across all classes (no drug-specific forms); AK’s 100% FMAP Tribal Health Compact (229+ federally recognized tribes; Alaska Area IHS + ANTHC operate 8 tribally managed hospitals + 72 tribal health centers + 148 village clinics) and largest-US-geography (663,267 sq mi, ~17% of US land area) are unique in the series
• Wyoming Medicaid GLP-1 Coverage (Pattern #47) — closest peer in the categorical-exclusion-with-three-FDA-label-carve-ins cohort: WY covers the SAME three indications as VT (Wegovy CV, Wegovy MASH, Zepbound OSA) but WY’s Zepbound OSA criteria are even LESS restrictive than VT’s (VT requires CPAP prescribed; WY requires only the sleep study within prior 12 months); WDH Pharmacy Services Manual Revision 27 (eff. April 15, 2026) page 8 codifies the exclusion as “Anorexiant products” (vs. VT’s bundled categorical sentence); both FFS-only architectures using Optum-family PBM (Optum for VT, OptumRx for WY post-April 15, 2026 migration); WY is smaller (~59,714 enrollees, smallest US state by population); non-expansion (2026 expansion defeated 7-23 and 5-26)
• Montana Medicaid GLP-1 Coverage (Pattern #46) — inverse architecture: clean categorical AOM exclusion with carve-outs UNVERIFIED pending MPQH PDF download; HB 245 (signed March 27, 2025) made expansion permanent (first state to convert sunsetting expansion to non-sunsetting) while SB 417 (Sen. Ellie Boldman AOM mandate) died 11-1 in committee March 1, 2025 — clean WHO-vs-WHAT split in a single 2025 session; PCCM (Passport to Health) architecture, not capitated MCO
• North Dakota Medicaid GLP-1 Coverage (Pattern #44) — middle-ground “covered for everything except obesity”: ND covers Wegovy MACE + Wegovy MASH + Zepbound OSA (most restrictive OSA carve-out in series, requiring 6-mo CPAP failure AND 6-mo semaglutide comprehensive weight-management program) + Ozempic/Victoza no-PA for antipsychotic-induced weight gain (T43.505 codes) + Imcivree + low-cost AOMs without PA but NOT Wegovy/Zepbound/Saxenda for standalone obesity; FFS-dominant + BCBSND-only expansion MCO under 1915(b) waiver; HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor 02/12/2025 (most decisive legislative no-vote in series); ND 2025 commercial EHB covers GLP-1s for morbid obesity (inverse of Medicaid posture)
• South Dakota Medicaid GLP-1 Coverage (Pattern #45) — structurally distinct exclusion architecture: where VT codifies its categorical AOM exclusion verbatim on the PDL with three drug-specific carve-out PA forms, SD operates a functional AOM exclusion by ABSENCE (no codified categorical sentence in the SD Medicaid Pharmacy Services Manual; the OptumRx SD-specific GLP-1 PA form pre-codes ONLY T2D as the indication checkbox); FFS-only architecture under DSS Division of Medical Services; ballot-initiative expansion (Amendment D 2022) plus uniquely constitutionalized 90% FMAP trigger on the Nov 3, 2026 ballot via Constitutional Amendment I
• Idaho Medicaid GLP-1 Coverage (Pattern #48) — codification-vs-non-codification contrast: where VT anchors a categorical bundled exclusion verbatim in regulation and codifies three FDA-label carve-outs in PDL, ID has NEITHER the codified categorical exclusion sentence NOR codified carve-outs — IDAPA 16.03.09.662 does NOT enumerate anti-obesity drugs as an excluded class. The exclusion operates through non-codification (silence in IDAPA + PDL placement + PA criteria). Bar to administrative carve-back-in is LOWER than VT’s codified architecture, but political compounding (HB 138 / HB 345 / HB 913 + Office of Group Insurance dropped GLP-1 obesity coverage Nov 1, 2025) makes change unlikely
• Kansas Medicaid GLP-1 Coverage (Pattern #43) — opposite categorical posture: KS covers Wegovy + Zepbound for obesity at adult BMI ≥ 30 (no carve-out gymnastics needed) and LOOSENED criteria in 2024-2025 by de-listing both drugs from Table 4 — the inverse of VT’s categorical-exclusion-plus-three-carve-outs architecture
• Rhode Island Medicaid GLP-1 Coverage (Pattern #40) — first state in series with active coverage + governor-proposed October 1, 2026 sunset (inverse comparison to VT)
• Maine MaineCare GLP-1 Coverage (Pattern #39) — closest peer in series; categorical exclusion with NO Wegovy MASH carve-out (more restrictive than VT)
• Nebraska Medicaid GLP-1 Coverage (Pattern #38) — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
• Utah Medicaid GLP-1 Coverage (Pattern #37) — legislative pilot-program coverage with 6/30/2026 sunset of in-lab attended PSG carve-out
• West Virginia Medicaid GLP-1 Coverage (Pattern #36) — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP
• Mississippi Medicaid GLP-1 Coverage (Pattern #35) — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages 12+ pathway
• 50-state Medicaid GLP-1 coverage map — full series overview with pattern taxonomy
• GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
• GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

1. Vermont Preferred Drug List effective April 17, 2026 — DVHA
2. Vermont Preferred Drug List effective January 1, 2026 — prior version for reference
3. PDL Communication / Changes bulletin (effective January 1, 2026)
4. Vermont PDL page (all historical revisions)
5. Semaglutide MACE/MASH Prior Authorization Form — Last Updated 04/2026
6. Zepbound OSA Prior Authorization Form
7. Pharmacy PA Forms index
8. General Prior Authorization Form
9. Pharmacy Benefits Administrator (Optum / Change Healthcare)
10. Pharmacy program bulletins index
11. Drug Coverage Lists index
12. DVHA Appeals, Fair Hearings and Grievances
13. DVHA Internal Appeals filing guide (PDF)
14. Vermont Medicaid General Provider Manual
15. Vermont Medicaid Portal
16. H.765 (2024) bill text — Rep. Mari Cordes
17. H.765 status
18. S.164 (2024) status — Sen. Ruth Hardy + Sen. Kesha Ram Hinsdale
19. Medicaid Program EE Q1 SFY26 Report (12/01/2025) — 178,842 total caseload
20. Code Vt. R. 13-001-008-X PART EIGHT — Appeals Process and Procedures
21. Human Services Board (Vermont)
22. KFF — Medicaid Coverage of and Spending on GLP-1s (January 16, 2026)
23. VtDigger — Flurry of legislation (February 18, 2024) — DVHA $75M fiscal estimate
24. CMS Managed Care state profile — Vermont (PCCM)
25. Vermont Legal Aid — Office of Health Care Advocate — 1-800-917-7787